tiprankstipranks
Trending News
More News >
Kaneka Corporation (JP:4118)
:4118
Advertisement

Kaneka (4118) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4118

Kaneka

(4118)

Select Model
Select Model
Select Model
Outperform 74 (OpenAI - 4o)
Rating:74Outperform
Price Target:
¥4,769.00
▲(10.98% Upside)
Kaneka's stock is supported by strong valuation metrics and stable technical indicators. Financial performance shows robust revenue growth and operational efficiency, though profitability and cash flow challenges need addressing. The absence of earnings call and corporate events data limits further insights.

Kaneka (4118) vs. iShares MSCI Japan ETF (EWJ)

Kaneka Business Overview & Revenue Model

Company DescriptionKaneka Corporation manufactures and sells polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan and internationally. It provides impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, and biodegradable polymer, engineering resin for injection molding, zero birefringence, acrylic film, and isobutylene-based thermoplastic elastomer products. The company also offers polypropylene and kanelite foams, extruded polystyrene foam insulation, polyimide film, transparent film for optical use, high thermal conductive graphite sheets, multi-layer insulation, transparent conductive film, and thermo-resistant, and light-resistant transparent resin products. In addition, it provides photovoltaic power generation systems for residences, public, and industrial installations; eco fur, flame-retardant, hair accessory, and new materials; organic EL lighting panels; and biosurfactant. Further, the company offers intervention, blood purification, gastroenterology intervention, testing equipment, regenerative medicine and cell therapy, and genetic diagnostic products; and low molecular pharmaceutical materials, affinity chromatography resin for purification of a monoclonal antibody, biopharmaceuticals, transdermal medicine, and innerwear with shock-absorbing pad. It also provides dairy products, margarine, fat and oils, whipping cream, filling, baker's yeast/ dough improver, processed fruits, butter, shortening, cacao butter alternatives, cream for kneading and other uses, frozen dough, spices, antifreeze materials; and pharma and supplemental nutrition solutions, including coenzyme, lactic-acid bacteria, and functional foodstuffs, as well as fertilizers. Kaneka Corporation was incorporated in 1949 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyKaneka generates revenue through multiple key streams, primarily from the sale of its specialty chemicals, which are used in a wide range of industries, including electronics, automotive, and construction. The company's pharmaceutical division contributes significantly to its earnings through the development and commercialization of prescription drugs and medical products. Additionally, Kaneka has established partnerships with various firms and research institutions to enhance its product offerings and expand its market reach, which further supports its revenue growth. The company also invests in biotechnology and health-related sectors, generating income through the sale of health supplements and functional foods.

Kaneka Financial Statement Overview

Summary
Kaneka demonstrates solid revenue growth and operational efficiency, supported by stable equity and robust operating cash flows. However, challenges persist in the form of declining net profit margins and negative free cash flow, largely driven by significant capital expenditures. The increase in debt levels requires careful monitoring to ensure financial stability.
Income Statement
72
Positive
Kaneka's income statement shows strong revenue growth with a compound annual growth rate (CAGR) of approximately 6.4% over the past five years. The gross profit margin has been relatively stable, with a slight improvement to 27.8% in 2025. However, the net profit margin shows a slight decline from previous periods, standing at 3.1% for 2025. EBIT and EBITDA margins have improved, indicating operational efficiency, but the declining net profit margin signals pressure on the bottom line, possibly due to increased expenses or cost of goods sold.
Balance Sheet
70
Positive
Kaneka's balance sheet indicates a stable equity position, with stockholders' equity rising to 471,937 million yen in 2025. The debt-to-equity ratio increased to 0.47, showing a moderate leverage level. The equity ratio improved slightly to 51.3%, suggesting a robust financial position. However, the rise in total debt over the years could pose potential risks if not managed carefully. Overall, the company maintains a balanced approach to leveraging debt while sustaining equity growth.
Cash Flow
65
Positive
The cash flow statement reveals challenges in free cash flow, which turned negative in 2025 at -9,931 million yen, due to high capital expenditures. Operating cash flow remains strong at 41,252 million yen, indicating good cash generation from core operations. The free cash flow to net income ratio is negative due to the capital intensity, but the operating cash flow to net income ratio stands favorably. While cash from operations is solid, the negative free cash flow suggests a need for careful capital management to avoid liquidity issues.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue807.50B807.20B762.30B755.82B691.53B577.43B
Gross Profit223.41B224.63B204.22B198.93B196.65B166.94B
EBITDA73.88B84.74B81.62B74.44B75.98B60.27B
Net Income22.54B25.31B23.22B23.01B26.49B15.83B
Balance Sheet
Total Assets920.22B920.14B870.21B782.64B726.96B667.43B
Cash, Cash Equivalents and Short-Term Investments44.35B45.64B43.97B41.87B41.95B47.92B
Total Debt212.31B223.06B195.09B175.94B132.83B119.34B
Total Liabilities428.71B427.72B395.82B346.22B314.76B286.39B
Stockholders Equity470.63B471.94B454.11B417.99B387.77B357.61B
Cash Flow
Free Cash Flow0.00-9.93B-3.35B-13.28B-5.82B31.64B
Operating Cash Flow0.0041.25B61.91B28.71B34.11B74.04B
Investing Cash Flow0.00-55.04B-58.77B-41.97B-39.59B-43.23B
Financing Cash Flow0.0014.45B-1.52B12.35B-1.10B-21.90B

Kaneka Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4297.00
Price Trends
50DMA
4254.26
Positive
100DMA
4157.64
Positive
200DMA
3880.75
Positive
Market Momentum
MACD
8.18
Negative
RSI
54.20
Neutral
STOCH
48.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4118, the sentiment is Positive. The current price of 4297 is above the 20-day moving average (MA) of 4251.60, above the 50-day MA of 4254.26, and above the 200-day MA of 3880.75, indicating a bullish trend. The MACD of 8.18 indicates Negative momentum. The RSI at 54.20 is Neutral, neither overbought nor oversold. The STOCH value of 48.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4118.

Kaneka Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$549.88B13.286.42%3.46%-6.27%40.98%
74
Outperform
$269.84B11.914.90%3.49%3.80%-11.14%
72
Outperform
$317.10B8.809.65%4.21%0.87%16.71%
71
Outperform
$343.22B12.277.05%2.72%-0.63%
69
Neutral
$495.98B9.9510.06%3.12%4.35%7.88%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
51
Neutral
$218.85B-41.36-1.26%4.85%-7.45%-71.68%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4118
Kaneka
4,297.00
705.25
19.64%
JP:4088
Air Water
2,262.50
425.79
23.18%
JP:4631
DIC
3,678.00
502.72
15.83%
JP:4182
Mitsubishi Gas Chemical Company
2,888.00
257.37
9.78%
JP:4208
UBE Industries
2,270.00
40.60
1.82%
JP:4205
Zeon
1,616.50
217.63
15.56%

Kaneka Corporate Events

Kaneka Corporation Executes Strategic Share Repurchase
Aug 12, 2025

Kaneka Corporation has completed a repurchase of 650,000 shares of its common stock for approximately 2.9 billion yen, as part of its strategy to enhance shareholder value and maintain flexible capital policies. This move is part of a broader plan to repurchase up to 3 million shares, reflecting the company’s commitment to adjusting its financial strategies in response to market conditions.

The most recent analyst rating on (JP:4118) stock is a Hold with a Yen4300.00 price target. To see the full list of analyst forecasts on Kaneka stock, see the JP:4118 Stock Forecast page.

Kaneka Corporation Announces Share Repurchase Plan
Aug 8, 2025

Kaneka Corporation announced its plan to repurchase up to 650,000 shares of its own stock through the Tokyo Stock Exchange’s ToSTNeT-3 system at a set price, as part of a broader strategy to repurchase up to 3 million shares by March 2026. This move is aimed at optimizing capital structure and potentially enhancing shareholder value, reflecting the company’s proactive approach to managing its financial resources.

The most recent analyst rating on (JP:4118) stock is a Hold with a Yen4800.00 price target. To see the full list of analyst forecasts on Kaneka stock, see the JP:4118 Stock Forecast page.

Kaneka Corporation Updates on Share Repurchase Program
Aug 1, 2025

Kaneka Corporation announced the status of its treasury stock repurchase program, initially resolved in May 2025. As of July 31, 2025, the company repurchased 446,600 shares for approximately 1.77 billion yen, as part of a broader plan to buy back up to 3 million shares by March 2026. This move is likely aimed at enhancing shareholder value and optimizing capital structure.

The most recent analyst rating on (JP:4118) stock is a Hold with a Yen4300.00 price target. To see the full list of analyst forecasts on Kaneka stock, see the JP:4118 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025